Pharma
EU risks €2bn in annual investment if pharma laws approved
Industry body warns new proposals will likely harm, rather than strengthen European competitiveness
The European Union could lose €2 billion of investment a year in medicines research and development if a law overhauling the bloc’s pharmaceutical regime goes ahead, an industry group warned Monday.
The European Commission has said it wants to shorten the standard period of patent protection for new medicines from eight to six years, as part of a wider plan to ensure affordable access to drugs and boost innovation.
It’s a measure that will dramatically ...
